Know Cancer

forgot password

Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma

Phase 1
18 Years
Open (Enrolling)

Thank you

Trial Information

Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma

This study is a multi-center, Phase 1 clinical trial to determine the safety and feasibility
of minimally invasive inguinal lymph node dissection for patients with melanoma. Licensed
surgeons who have undergone special training, including a course at the Mayo Clinic
Rochester in minimally invasive lymph node dissection (MILND) will perform the new procedure
at their home institutions. The study will characterize the learning curve of MILND in the
clinical setting, and evaluate the safety of the new operative technique.

The hypotheses for this study are: 1) minimally invasive groin dissection is a safe
procedure. 2) a structured educational training program is a feasible and effective method
to train practicing surgeons in this novel procedure and 3) pre-course generic laparoscopic
technical skills correlate with minimally invasive superficial groin dissection performance
in a clinical setting, including operative oncologic standards and safety metrics.

Inclusion Criteria

Inclusion criteria:

- Malignant melanoma present in an inguinal nodal basin requiring superficial inguinal
lymph node dissection.

- Plan for superficial inguinal dissection alone or combined superficial inguinal and
deep pelvic node dissection is acceptable.

- Clinical or radiographic evidence of superficial inguinal lymph node disease or a
prior positive single lymph node biopsy of the superficial inguinal basin as an
indication for superficial inguinal lymph node disease is acceptable.

- Patients must be Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
and be healthy enough to undergo a general anesthetic (no epidural or spinal

- Female patients of child bearing age must have a negative pregnancy test, be
surgically sterile or post-menopausal greater than 1 year.

- Patients must be able to return to surgical facility for 30 and/or 90 day (+/- 20
days) for follow-up appointment.

Exclusion Criteria:

- Prior ipsilateral superficial inguinal lymph node dissection

- Invasion or ulceration of inguinal nodal disease into the overlying skin

- Prior radiation therapy to the same regional nodal basin.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Proficiency score per surgery

Outcome Description:

The proficiency score is a function of the lymph nodes pathologically identified, the amount of blood transfused and the operative time. The range is 0 to 3, with higher proficiency in performing the procedure being 3.

Outcome Time Frame:

Approximately 90 days following surgical procedure

Safety Issue:


Principal Investigator

James Jakub, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mayo Clinic


United States: Institutional Review Board

Study ID:




Start Date:

June 2012

Completion Date:

June 2013

Related Keywords:

  • Melanoma
  • Melanoma
  • Lymph Nodes
  • Lymph Node Dissection
  • Minimally invasive
  • Melanoma



Memorial Sloan Kettering Cancer Center New York, New York  10021
H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida  33612
Fox Chase Cancer Center Philadelphia, Pennsylvania  19111
Northwestern Memorial Hospital Chicago, Illinois  60611
John Wayne Cancer Institute Santa Monica, California  90404
MetroHealth Medical Center Cleveland, Ohio  44109
Mayo Clinic in Arizona Scottsdale, Arizona  85259-5404
Mayo Clinic in Florida Jacksonville, Florida  32224
Duke University Medical Center Durham, North Carolina  27710
University of Wisconsin Madison,, Wisconsin  53792-5666
The Ohio State University Medical Center Columbus, Ohio  43210